This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Gastrointestinal disease				
Colitis	BCL2 binding component 3 (BBC3; PUMA)	<p>Studies in mice and in patient samples suggest that inhibiting PUMA could help treat ulcerative colitis (UC). In patient samples, PUMA expression was significantly greater in tissues with moderate to severe pathology than in tissues showing mild pathology ($p < 0.05$). In a mouse model of chemically induced colitis, <i>Puma</i> deficiency led to lower disease severity than wild-type <i>Puma</i> expression ($p < 0.01$). Next steps could include evaluating PUMA inhibitors in mouse models of colitis.</p> <p>SciBX 4(15); doi:10.1038/scibx.2011.428 Published online April 14, 2011</p>	Patent and licensing status unavailable	<p>Qiu, W. <i>et al. J. Clin. Invest.</i>; published online April 1, 2011; doi:10.1172/JCI42917</p> <p>Contact: Lin Zhang, University of Pittsburgh Cancer Institute, Pittsburgh, Pa. e-mail: zhanglx@upmc.edu</p>